We have conducted a double-blind comparative study of flutamide and chlormadinone
acetate (CMA) on patients with stage C or D prostatic cancer and with no prior experience of …

Flutamide is a non‐steroidal anti‐androgen which has been used to treat prostate cancer.
Results to date indicate that flutamide is as effective as other conventional therapy. It has …

We analyzed clinical effects of flutamide as a second‐line agent for maximum androgen
blockade (MAB) in patients with relapsing prostate cancer who received bicalutamide as the …

Fifty-two patients with previously untreated metastatic carcinoma of the prostate were treated
with flutamide 250 mg tid. Response was classified according to objective and subjective …

Purpose: To compare in a randomized clinical trial the therapeutic efficacy of the
nonsteroidal antiandrogen flutamide 250 mg tid to testicular androgen suppression by …

Ten men with newly diagnosed generalised cancer of the prostate were treated with
Flutamide (SCH 13521). After 18 months of treatment, one patient had stable disease and …

BACKGROUND More than 50,000 male patients received hormonal therapy for metastatic
prostate carcinoma in 1995. Nonsteroidal antiandrogens, such as flutamide, when used in …

Background/Aim: There are few reports that verify the relationship between the therapeutic
effects of flutamide and novel androgen receptor-targeted agents. We aimed to evaluate the …

PURPOSE: Time to progression (TTP), overall survival, and quality of life (QL) were
compared in patients with hormone-resistant prostate cancer (HRPC) treated with …

Background. Flutamide withdrawal has been reported to be therapeutically efficacious for
patients with hormone‐refractory prostate cancer, with a reported prostate specific antigen …